Newsroom
Keeping up with GAIA-BT
Everything from our partnerships, products and press.
Featured story
Client30 OCT 2026
Cyron Therapeutics' Follow-up Validation Confirms Binding Recovery in Antibody Prototype Designed with GAIA-Phil™
Read more
Product7 OCT 2026
GAIA-BT Secures Exclusive Rights to HAETAE and HiRecon Under Definitive Technology Transfer Agreement with KRIBB
Read more
Awards & Grants22 SEP 2026
GAIA-BT Selected as a Resident Company at Seoul AI Hub
Read more
Cyron Therapeutics' Follow-up Validation Confirms Binding Recovery in Antibody Prototype Designed with GAIA-Phil™
29 UPDATES
Company news
- Client30 OCT 2026Cyron Therapeutics' Follow-up Validation Confirms Binding Recovery in Antibody Prototype Designed with GAIA-Phil™
- Product7 OCT 2026GAIA-BT Secures Exclusive Rights to HAETAE and HiRecon Under Definitive Technology Transfer Agreement with KRIBB
- Awards & Grants22 SEP 2026GAIA-BT Selected as a Resident Company at Seoul AI Hub
- Client24 JUN 2026GAIA-BT to Lead "AI Optimization" of Cyron Therapeutics' Cancer Drug Candidates
- Partnership20 MAY 2026GAIA-BT Signs Letter of Intent with Prosilico for AI-Based Drug Discovery Collaboration
Media
GAIA-BT in the press
- Feature31 OCT 2026가이아비티, 멀티에이전트 AI로 신약 후보 평가·환자 반응 예측 [서울AI허브 2027]IT ChosunRead — (opens IT Chosun in a new tab)
- Interview12 OCT 2026GAIA-BT는 ‘AI 신약개발 회사’가 아닌 AI와 사람, 병원과 연구기관, 그리고 실제 환자에서 얻은 정보를 하나로 연결해 신약개발의 의사결정 방식을 바꾸는 운영시스템을 개발하는 회사입니다.[판교허브 밸류업] “바이오 AI 에이전트로 임상 실패 방어”…가이아비티의 담대한 도전WowtaleRead — (opens Wowtale in a new tab)
